U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07013110) titled 'An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis' on May 07.
Brief Summary: This clinical study is a multi-center, randomized, double-blind, placebo-controlled, outpatient study comparing the efficacy of combination of dnaJP1 peptide and hydroxychloroquine versus combination of placebo and hydroxychloroquine in patients with moderately to severely active RA who are naive to cs-, b-, tsp.-DMARDs.
A sample size of 124 patients will be enrolled in the study. Each patient will receive either combination of dnaJP1 peptide and hydroxychloroquine or combination of placebo and hydroxychloroquine in ...